1

Y-mAbs

Drug development oncology

www.ymabs.com

HBM contact: Dr Ivo Staijen, Dr Matthias Fehr

Company status: public

YmAbs is a clinical stage biotechnology company specialized in developing novel antibody therapeutics to treat cancer. Several ongoing late-stage clinical trials significantly improve survival rates for critical unmet medical needs among cancer patients including pediatric patients.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171